Skip to main content
19 search results for:

Trametinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 22-06-2018 | Melanoma | Highlight | Teaser
    medwireNews approvalsWatch

    Adjuvant dabrafenib–trametinib approved for mutated melanoma

    Find out more about this US FDA decision here

  2. 02-05-2018 | Melanoma | News | Article
    approvalsWatch

    Adjuvant dabrafenib–trametinib approved for mutated melanoma

    medwireNews : US patients with lymph node-positive melanoma harboring the BRAF V600E or V600K mutations may now be treated with adjuvant dabrafenib and trametinib.

  3. 14-05-2018 | Anaplastic thyroid carcinoma | News | Article
    approvalsWatch

    Dabrafenib–trametinib combination receives anaplastic thyroid cancer approval

    By Lynda Williams medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group See also :  Adjuvant dabrafenib-trametinib approved for mutated melanoma Dabrafenib-trametinib approved for metastatic BRAF V600E-positive NSCLC

  4. 11-09-2017 | Melanoma | ESMO 2017 | Article
    ESMO 2017

    Dabrafenib plus trametinib cuts melanoma relapse risk significantly

    Adjuvant combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib halves the risk for relapse in patients with stage III melanoma with BRAF V600E or V600K mutations, show results from the COMBI-AD trial.

  5. 18-09-2017 | Non-small-cell lung cancer | ESMO 2017 | Article
    ESMO 2017

    Dabrafenib–trametinib actively targets BRAF V600E-mutant metastatic NSCLC

    Dabrafenib in combination with trametinib provides long-lasting antitumor activity in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer, with a tolerable safety profile, researchers report.

  6. 10-07-2017 | FDA | News | Article
    approvalsWatch

    Dabrafenib–trametinib approved for metastatic BRAF V600E-positive NSCLC

    Patients whose BRAF V600E mutation is confirmed by an FDA-approved test may be given dabrafenib 150 mg twice daily plus trametinib 2 mg once daily, following results from the Study BRF 113928 open-label trial.

  7. 09-10-2017 | Dabrafenib | Article

    Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

    Long G et al.  J Clin Oncol  2018; 36(7): 667-673. doi:10.1200/JCO.2017.74

  8. 11-09-2017 | Dabrafenib | Article

    Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    Planchard D et al. Lancet Oncol  2017; 18(10):1307-1316. doi:10.1016/S1470-2045(17)30679-4

  9. 04-03-2017 | Melanoma | Article

    Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

    Schreuer M et al. Lancet Oncol  2017; 18(4): 464-472. doi:10.1016/S1470-2045(17)30171-7

  10. 09-07-2019 | Non-small-cell lung cancer | News | Article

    Vemurafenib monotherapy has potential for BRAF-mutated NSCLC

    Noting that the combination of dabrafenib and trametinib has been approved in Europe and the USA for individuals with BRAF V600E mutation-positive NSCLC, the researchers say “combination therapy consisting of a BRAF inhibitor and an MEK inhibitor has now become standard of care” for these patients.

  11. 26-01-2018 | Melanoma | News | Article

    Neoadjuvant therapy may benefit patients with high-risk melanoma

    Receiving neoadjuvant plus adjuvant dabrafenib and trametinib significantly improves event-free survival compared with standard care in patients with high-risk melanoma, phase II study findings indicate.

  12. 23-04-2018 | Melanoma | News | Article

    Encorafenib–binimetinib a new option for BRAF-mutated melanoma

    The researchers also note that the incidence of pyrexia and photosensitivity – adverse events known to occur with the dabrafenib–trametinib and vemurafenib–cobimetinib combinations, respectively – were “infrequent” with encorafenib and binimetinib.

  13. 19-05-2017 | Breast cancer | News | Article

    In other news

    “These results support long-term use of [dabrafenib plus trametinib] as a first-line treatment strategy” in these patients, the COMBI-d investigators conclude in the Annals of Oncology .

  14. 22-08-2017 | Ovarian cancer | Article

    Contemporary treatment strategies for rare epithelial ovarian cancers

    Bergstrom JE, Fader AN, Gershenson DM. Curr Obstet Gynecol Rep 2017;6:228–236. doi:10.1007/s13669-017-0217-z

  15. 16-08-2017 | Melanoma | News | Article

    Final BRIM-3 data confirm vemurafenib survival benefit over dacarbazine

    They add that ”[s]ince the approval of vemurafenib monotherapy in 2011, the treatment landscape for BRAF-mutated metastatic melanoma has changed considerably,” with combinations of dabrafenib plus trametinib and cobimetinib plus vemurafenib now approved first-line therapies.

  16. 11-11-2016 | Treatment | Article

    Combinatorial immunotherapy for melanoma

    Trametinib showed an RR of 22%, median PFS of 4.8 months and OS of 81% at 6 months versus an RR of 8%, median PFS of 1.5 months and OS of 67% at 6 months with chemotherapy. 17 Although trametinib did not perform as well as the BRAF inhibitors as a single agent, it did have a better serious AE profile of 21% versus 39% with chemotherapy.

  17. 06-12-2016 | Colorectal cancer | Article

    From tumour heterogeneity to advances in precision treatment of colorectal cancer

    Combined inhibition of BRAF and MEK using dabrafenib and trametinib in  BRAF -mutant mCRC resulted in inhibition of MAPK signalling in all patients, but clinical efficacy was only demonstrated in a subset of patients 114 .

  18. 17-05-2016 | Triple-negative breast cancer | Article

    Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease

    Little data on the efficacy of MEK inhibitors in TNBC have been published, but, importantly, in a phase Ib trial in patients with solid tumours ( n  = 31) treated with gemcitabine and trametinib (an orally available potent inhibitor of MEK1/2), the only complete response to therapy occurred in a patient with mTNBC 119 .

  19. 23-04-2018 | Non-small-cell lung cancer | Article

    BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall

    Leonetti A et al. Cancer Treat Rev  2018; 66: 82-94. doi:10.1016/j.ctrv.2018.04.006

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.